774
F. Wang et al. / Journal of Pharmaceutical Sciences 105 (2016) 773e785
DCF are also known to exert an antiproliferative effect on fibroblasts
and keratinocytes,7 which may counteract their anti-inflammatory
effect in the early stages of the wound healing cycle. Further studies
in acute wounds have demonstrated that even though DCF reduced
fibroblast numbers in an incisional acute wound, DCF did not
impair normal healing.8 The observation that DCF has potential
therapeutic activities important to the management of chronic
wounds led to the intriguing possibility that it would be clinically
efficacious to deliver therapeutic levels of DCF into chronic
wounds.9
Experimental
Materials
Diclofenac was purchased from Beta Pharm Company Ltd.
(batch number: 201006280; assay: 99.12%; Shanghai, China). All
other solvents or reagents were HPLC or analytical reagent grade.
Supplementary Information contains further information for HPLC
method validation, preparation of lactam (4), and additional kinetic
data.
We sought to build DPCs where DCF was attached pendent to
the polymer backbone through an ester linkage, which is labile in
Synthesis of Diclofenac Esters
a
physiological environment and provides a mechanism for
controlled release. The polymer could be processed into fiber form
and incorporated into wound care dressings with a key perfor-
mance criterion that they must release therapeutic amounts of DCF
in a controlled manner when exposed to wound exudate.
Synthesis of the diclofenacepolymer conjugate involves reac-
tion of diclofenac conjugated via an ester linkage to a diol, as a drug
incorporating monomer, with a comonomer (i.e., a diisocyanate) to
Preparation of 1,3-Dihydroxypropan-2-yl 2-(2-((2,6-Dichlorophenyl)
Amino)Phenyl)Acetate (DCF-2-MG)(3b)
To a mixture of diclofenac (11.47 g, 38.7 mmol), DMAP (0.25, 2.0
mmol), and cis-1,3-benzylidene glycerol (6.99 g, 38.8 mmol), a so-
lution of DCC (10.01 g, 48.5 mmol) in anhydrous DCM (500 mL) was
added drop wise at 0ꢀC over a period of 30 min. The reaction was
stirred at 0ꢀC for 2 h. The crude material was purified via column
chromatography on silica gel (20% ethyl acetate/hexanes as eluent)
to give 2-phenyl-1,3-dioxan-5-yl 2-{2-[(2,6-dichlorophenyl)amino]
phenyl}acetate in 68% yield as an off-white solid. 1H NMR (200 MHz,
CDCl3) * 7.71-7.27 (m, 8H), 7.27-7.09 (m, 1H), 7.09-6.88 (m, 3H), 6.63
(d, J ¼ 7.9 Hz, 1H), 5.59 (s, 1H), 4.78 (s, 1H), 4.26 (dd, J ¼ 40.1, 12.6 Hz,
4H), 4.01 (s, 2H). 13C NMR (50 MHz, CDCl3) * 172.65, 142.88, 137.91,
137.86, 131.09, 129.52, 129.12, 128.90, 128.33, 128.14, 126.10, 124.42,
124.07, 122.19, 118.45, 101.17, 68.92, 66.91, 38.60. ESI-MS: m/z 460
produce
a polyurethane-based DPC. The drugincorporating
monomer is a prodrug, the hydrolytic behavior of which can be
studied independently to confirm the lability of the ester linkage
and to better understand diclofenac release from the final DPC
product.
The purpose of this study was to (1) confirm that hydrolysis of
an aryl ester construct was faster than an alkyl ester, (2) show that
DCF was the predominant product of hydrolysis, (3) examine the
stability of DCF and its lactam alone, (4) understand the relation-
ships between rates of hydrolysis and pH, and (5) explore the utility
of the constructs for design of a wound-responsive product.
Preparation of DPCs of DCF has previously been attempted. Two
groups have described the use of standard ester linkages with
nonbiodegradable polymethacrylate polymer backbones.10,11 In
both cases, the drug release profile was measured with a direct UV
method that would not differentiate between DCF and its lactam
degradation product.
A number of other diclofenac alkyl ester prodrugs with ester
linkages have been made.10-15 Bonina et al.13 reported chemical
hydrolysis half-lives in the range 400e500 h (pH 7.4 buffer, 32ꢀC)
for an homologs series of polyoxyethylene ester prodrugs. Tam-
mara et al.15 produced a series of morpholinoalkyl esters of DCF
with reported chemical hydrolysis half-lives in the range 3e34 h
(pH 7.4 buffer, 37ꢀC). Both the disappearance of the prodrug and the
formation of DCF were measured, with mass balance achieved.
Jilani et al.14 made some hydroxyethyl esters of DCF and reported a
chemical hydrolysis half-life of about 36 h (pH 7.4, 37ꢀC). Bonina
et al.,13 Tammara et al.,15 and Jilani et al.14 all used HPLC methods to
quantify the prodrug separately from DCF and none reported any
observations regarding the formation of lactam (4).
37
37
(3%, Mþ, C24
H H
Cl2NO4), 459 (13%, Mþ, C24 Cl35ClNO4), 457 (15%,
21 21
35
Mþ, C24
H
21
Cl2NO4), 242 (11), 214 (100), 103 (15). IR nmax (cmꢁ1):
3320, 2855, 1717, 1504, 1451, 1142, 1080, 908, 728, 697.
1-(2,6-Dichlorophenyl)indolin-2-one (diclofenac lactam) (4)
was also isolated as a by-product in 30% yield. Spectral data were
consistent both with that reported and an authentic sample (see
Supporting Information).
2-Phenyl-1,3-dioxan-5-yl
2-{2-[(2,6-dichlorophenyl)amino]
phenyl}acetate (3.13 g, 6.8 mmol), 10% (w/w) palladium on carbon
(0.31 g) in ethyl acetate (60 mL) was hydrogenated under one at-
mosphere of hydrogen (balloon) for 16 h at room temperature. The
catalyst was removed by filtration through Celite. The crude ma-
terial was purified by reslurrying and filtration from 30% ethyl ac-
etate/hexanes. The title compound (3b) was obtained in 71% yield
as an off-white solid. 1H NMR (200 MHz, DMSO) * 7.68-7.42 (m, 2H),
7.29-6.91 (m, 4H), 6.91-6.69 (m, 1H), 6.25 (d, J ¼ 7.8 Hz, 1H), 4.90-
4.62 (m, 3H), 3.79 (s, 2H), 3.65-3.39 (m, 4H). 13C NMR (50 MHz,
DMSO) * 171.93, 143.27, 137.57, 131.29, 131.21, 131.05, 129.58, 128.12,
126.32, 123.89, 121.12, 116.33, 76.87, 60.15, 37.72. ESI-MS: m/z 373
37
37
(2%, Mþ, C17
H H
Cl2NO4), 371 (12%, Mþ, C17 Cl35ClNO4), 369 (18%,
17 17
35
Mþ, C20
H Cl2NO4), 295 (4), 279 (11), 277, (16), 242 (29), 216 (37)
21
214 (100), 180 (13). IR nmax (cmꢁ1): 3285, 2943, 1708, 1579, 1509,
Other NSAIDepolymer conjugates16 have been made to com-
pare hydrolysis rates for alkyl esters with aryl esters, with faster
drug release observed with the aryl ester. Also, some evidence
suggesting release rates were greater in more strongly basic media
was found. This has important implications for wound care, as it
offers the potential to develop a wound-responsive product.17 The
pH of normal skin is usually approximately 5.5, with a normal range
of 4.0-7.018 and the pH of serum (or acute wound exudate) is 7.35-
7.4519; chronic wound exudate is marked by an elevated pH, often
1450, 1289, 1046, 770, 743.
Preparation of 1,3-Dihydroxypropan-2-yl 4-(2-(2-((2,6-Dichlorophenyl)
Amino)Phenyl)Acetoxy) Benzoate (3c)
Using the procedure described above, 1,3-dihydroxypropan-2-yl
4-(2-(2-((2,6-dichlorophenyl)amino)phenyl)acetoxy) benzoate (3c)
was prepared in two steps from diclofenac in 62% and 67%, respec-
tively. Diclofenac lactam (4) was also isolated as a by-product from
the first step in 37% yield. 1H NMR (200 MHz, CDCl3) * 8.26-7.86 (m,
2H), 7.34 (d, J ¼ 8.0 Hz, 3H), 7.23-7.09 (m, 3H), 7.07-6.88 (m, 2H),
6.70-6.48 (m, 2H), 5.14 (p, J ¼ 4.7 Hz, 1H), 4.07 (s, 2H), 3.94 (d, J ¼ 4.7
Hz, 4H), 2.50 (bs, 2H). 13C NMR (50 MHz, CDCl3) * 170.10, 154.43,
142.66, 137.63, 131.38, 131.03, 129.44, 128.85, 128.41, 127.54, 124.21,
123.48, 122.37, 121.71, 118.59, 75.81, 62.43, 38.53. ESI-MS: m/z 493
in the range 8.0-8.9.20,21
A wound bed microenvironment-
responsive product would release more drug during the periods
of active wound exudation, driven by the high pH of the wound,
and less drug as pH of the wound microenvironment decreases
because of wound healing. That is, ideally the DCF release rate
profile is pH dependent.
37
37
(2%, Mþ, C24
H H
Cl2NO6), 491 (6%, Mþ, C24 Cl35ClNO6), 489 (8%, Mþ,
21 21